ROIV (Roivant Sciences) Valuation Rank


ROIV Roivant Sciences Ltd ROIV
55 GF Score
Price $33.81
GF Value $10.45
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roivant Sciences Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Roivant Sciences Valuation Rank Related Terms

ROIV
55GF Score
Roivant Sciences Ltd ROIV
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Roivant Sciences (ROIV) Overvalued in 2026?

Based on GuruFocus' analysis, Roivant Sciences stock appears to be overvalued. The current stock price of $33.81 is trading 223.5% above its estimated GF Value™ of $10.45. GuruFocus considers Roivant Sciences to be Significantly Overvalued.

Key valuation signals for ROIV:

  • Valuation Rank:
  • GF Value™: $10.45 vs. price of $33.81 (223.5% above fair value)
  • GF Score™: 55/100 with 7 warning signs

No single metric tells the full story. See the ROIV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Roivant Sciences Business Description

Other Exchanges 87S:Germany
Address 50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
55GF Score

Get the complete analysis for ROIV

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$33.81
Price
$10.45
GF Value